The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

T he US Food and Drug Administration (FDA) has expanded approval of Moderna’s respiratory syncytial virus (RSV) vaccine to include younger adults at risk, though its still uncertain whether the ...

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease ACCESS Newswire Updated June 12, 2025 7:42 PM ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

The FDA approved mRESVIA in adults aged 60 or older last year, but with a lower efficacy label indicating the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and ...

Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says. Published: June 12, 2025 at 7:51 p.m. ET. ... The FDA previously approved mResvia for adults aged 60 years and older in May 2024.

Moderna’s RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV ...